Published in

Elsevier, International Journal of Cardiology, (178), p. 117-123

DOI: 10.1016/j.ijcard.2014.10.125

Links

Tools

Export citation

Search in Google Scholar

One-year outcome following biological or mechanical valve replacement for infective endocarditis.

Journal article published in 2015 by François Delahaye, Franz Wiesbauer, Ana Cláudia Passos de Brito, Regina Aparecida de Medeiros Tranchesi, Auristela de Oliveira Ramos, Clara Weksler, Barbora Zaloudikova, F. Delahaye, Liliana Clara, Marisa Sanchez, José Casabé, Claudia Cortes, Chu Vh, V. H. Chu, Francisco Nacinovich and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Background : Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality.Methods and results : Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement.Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p = 0.0009) and 25.3% vs 16.6% (p